BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

a man taking medication imageNovember 10 2017

Doxycycline should not be used for post-exposure prophylaxis (PEP) for sexually transmitted infections, says new guidance. Any potential benefits are “outweighed by the considerable potential for antibiotic resistance to develop in STIs and other bacteria.”

Members of the public who may be searching online for doxycycline PEP should be advised that antibiotics should only be prescribed by a health professional and use diagnostic testing.

A position statement issued jointly by Public Health England and the British Association for Sexual Health and HIV (BASHH) says more research is needed to assess the wider impact of prophylactic doxycycline on antimicrobial resistance (AMR) at an individual and population level. Instead, the organisations state: “We recommend the use of antibiotics as prescribed by a healthcare professional and as indicated by the results of a suitable diagnostic test.”

The statement refers to a study published earlier this year which had found that doxycycline PEP had halved the rates of bacterial STIs in men who have sex with men (MSM), in an extension of the French IPERGAY trial. “Many of the online companies selling HIV Pre-exposure Prophylaxis (PrEP) in the form of tenofovir disoproxil fumarate 300mg / emtricitabine 200mg are now making doxycycline available to UK buyers,” says the statement.

“A high rate of STIs without doxycycline PEP was shown (69.7 events per 100-person years of follow-up) and the antibiotic strategy showed an overall reduction in STI incidence of 47%. There was a significant decrease in chlamydia and syphilis incidence with reductions of 70 and 73% respectively in intent to treat analyses but no clear benefit was shown for gonorrhoea, likely due to the high rate of doxycycline resistance already developed.”

The PHE /BASHH statement adds: “For those at risk, following condomless sex, we recommend STI testing at appropriate window periods and the treatment of any infections identified should be prescribed by a healthcare professional and be in line with published national guidance. We recommend that the use of doxycycline PEP should be restricted to the research setting at present.”

Links:
PHE announcement       
BASHH announcement  
PHE/BASHH ‘Position Statement on Doxycycline as PostExposure Prophylaxis for Sexually Transmitted Infections’ November 2017                  

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...